The Respiratory Syncytial Virus (RSV) Therapeutics Global Market Report 2023, provides comprehensive information on the respiratory syncytial virus (rsv) therapeutics market across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa for the 27 major global industries. The report covers a ten year historic period – 2010-2021, and a ten year forecast period – 2023-2032.
Learn More On The Respiratory Syncytial Virus (RSV) Therapeutics Market’s Growth:
https://www.thebusinessresearchcompany.com/report/respiratory-syncytial-virus-rsv-therapeutics-global-market-report
The global respiratory syncytial virus (RSV) therapeutics market is expected to grow from $1.02 billion in 2022 to $1.27 billion in 2023 at a compound annual growth rate (CAGR) of 25.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and resulted in increased interest rates affecting many markets across the globe. The respiratory syncytial virus (RSV) therapeutics market is expected to reach $3.02 billion in 2027 at a CAGR of 24.1%.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample_request?id=12601&type=smp
Developing new drugs and vaccines with better efficacy is a key trend gaining popularity in the respiratory syncytial virus (RSV) therapeutics market. Major companies operating in the respiratory syncytial virus (RSV) therapeutics market are focused on developing new drugs and vaccines to sustain their position in the market. For instance, in May 2023, Pfizer Inc., a US-based pharmaceutical manufacturing company, received approval from the Food and Drug Administration, a US-based federal agency responsible for protecting and promoting public health, for ABRYSVO. The bivalent RSV prefusion F (RSVpreF) vaccine ABRYSVO (Respiratory Syncytial Virus Vaccine) is administered to prevent lower respiratory tract sickness caused by RSV in people 60 and older. ABRYSVO is an unadjuvanted vaccine made up of a pair of preF proteins tailored to maximize immunity to RSV A and B varieties, and it has been clinically proven to be safe and productive.
The respiratory syncytial virus (rsv) therapeutics market is segmented:
1) By Drug: Palivizumab, Ribavirin, Other Drugs
2) By Treatment: Immune Prophylaxis, Supportive Care, Antiviral Medications
3) By Dosage Form: Oral, Injectable, Other Dosage Forms
4) By Patient Type: Pediatrics, Adults
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Top Major Players:
Johnson & Johnson
F. Hoffmann-La Roche Ltd
Merck & Co. Inc
AbbVie Inc
Novartis AG
North America was the largest region in the respiratory syncytial virus (RSV) therapeutics market in 2022
The table of contents in TBRC’s respiratory syncytial virus (rsv) therapeutics market report includes:
1. Executive Summary
2. Respiratory Syncytial Virus (RSV) Therapeutics Market Characteristics
3. Respiratory Syncytial Virus (RSV) Therapeutics Market Trends And Strategies
4. Respiratory Syncytial Virus (RSV) Therapeutics Market – Macro Economic Scenario
5. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size and Growth
………………………………………………………………………
32. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Competitive Benchmarking
33. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Respiratory Syncytial Virus (RSV) Therapeutics Market
35. Respiratory Syncytial Virus (RSV) Therapeutics Market Future Outlook and Potential Analysis
36. Appendix
Learn About Us:
The Business Research Company is a market intelligence firm that pioneers in market, company, and consumer research. TBRC’s specialist consultants are located globally and are experts in a wide range of industries that include healthcare, manufacturing, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries. Through the report businesses can gain a thorough understanding of the market’s size, growth rate, major drivers and leading players.
Read Related Reports:
https://topprnews.com/led-light-emitting-diode-neon-lights-market/
https://goodprnews.com/led-light-emitting-diode-neon-lights-market/
https://topprnews.com/managed-data-center-services-market/
https://goodprnews.com/managed-data-center-services-market/
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn:https://in.linkedin.com/company/the-business-research-company
Twitter:https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Healthcare Blog:https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
The asset reliability software global market report 2024 from The Business Research Company provides comprehensive…
The aortic endograft global market report 2024 from The Business Research Company provides comprehensive market…
The advanced therapeutics pharmaceutical outsourcing global market report 2024 from The Business Research Company provides…
The vertical take-off and landing (vtol) uav global market report 2024 from The Business Research…
The solar cells global market report 2024 from The Business Research Company provides comprehensive market…
The security analytics global market report 2024 from The Business Research Company provides comprehensive market…